Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.

Taylor J, Pavlick D, Yoshimi A, Marcelus C, Chung SS, Hechtman JF, Benayed R, Cocco E, Durham BH, Bitner L, Inoue D, Chung YR, Mullaney K, Watts JM, Diamond EL, Albacker LA, Mughal TI, Ebata K, Tuch BB, Ku N, Scaltriti M, Roshal M, Arcila M, Ali S, Hyman DM, Park JH, Abdel-Wahab O.

J Clin Invest. 2018 Aug 31;128(9):3819-3825. doi: 10.1172/JCI120787. Epub 2018 Aug 6.

2.

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.

Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, Nagasubramanian R, Davis JL, Rudzinski E, Feraco AM, Tuch BB, Ebata KT, Reynolds M, Smith S, Cruickshank S, Cox MC, Pappo AS, Hawkins DS.

Lancet Oncol. 2018 May;19(5):705-714. doi: 10.1016/S1470-2045(18)30119-0. Epub 2018 Mar 29. Erratum in: Lancet Oncol. 2018 May;19(5):e229.

3.

TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening.

Albert CM, Davis JL, Federman N, Casanova M, Laetsch TW.

J Clin Oncol. 2019 Feb 20;37(6):513-524. doi: 10.1200/JCO.18.00573. Epub 2018 Dec 28.

PMID:
30592640
4.

TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.

Kummar S, Lassen UN.

Target Oncol. 2018 Oct;13(5):545-556. doi: 10.1007/s11523-018-0590-1.

PMID:
30276762
5.

Larotrectinib for the treatment of TRK fusion solid tumors.

Laetsch TW, Hawkins DS.

Expert Rev Anticancer Ther. 2019 Jan;19(1):1-10. doi: 10.1080/14737140.2019.1538796. Epub 2018 Oct 24.

PMID:
30350734
6.

Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3-Positive Acute Myeloid Leukemia.

Smith KM, Fagan PC, Pomari E, Germano G, Frasson C, Walsh C, Silverman I, Bonvini P, Li G.

Mol Cancer Ther. 2018 Feb;17(2):455-463. doi: 10.1158/1535-7163.MCT-17-0419. Epub 2017 Dec 13.

7.

Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.

Hsiao SJ, Zehir A, Sireci AN, Aisner DL.

J Mol Diagn. 2019 Jul;21(4):553-571. doi: 10.1016/j.jmoldx.2019.03.008. Epub 2019 May 7. Review.

8.

Inhibiting TRK Proteins in Clinical Cancer Therapy.

Lange AM, Lo HW.

Cancers (Basel). 2018 Apr 4;10(4). pii: E105. doi: 10.3390/cancers10040105. Review.

9.

Targeting TRK family proteins in cancer.

Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS.

Pharmacol Ther. 2017 May;173:58-66. doi: 10.1016/j.pharmthera.2017.02.006. Epub 2017 Feb 4. Review.

PMID:
28174090
10.

Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.

Hechtman JF, Benayed R, Hyman DM, Drilon A, Zehir A, Frosina D, Arcila ME, Dogan S, Klimstra DS, Ladanyi M, Jungbluth AA.

Am J Surg Pathol. 2017 Nov;41(11):1547-1551. doi: 10.1097/PAS.0000000000000911.

11.

NTRK fusion-positive cancers and TRK inhibitor therapy.

Cocco E, Scaltriti M, Drilon A.

Nat Rev Clin Oncol. 2018 Dec;15(12):731-747. doi: 10.1038/s41571-018-0113-0. Review.

PMID:
30333516
12.

Molecular characterization of cancers with NTRK gene fusions.

Gatalica Z, Xiu J, Swensen J, Vranic S.

Mod Pathol. 2019 Jan;32(1):147-153. doi: 10.1038/s41379-018-0118-3. Epub 2018 Aug 31.

PMID:
30171197
13.

Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins.

Kheder ES, Hong DS.

Clin Cancer Res. 2018 Dec 1;24(23):5807-5814. doi: 10.1158/1078-0432.CCR-18-1156. Epub 2018 Jul 9. Review.

PMID:
29986850
14.

Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers.

Chen Y, Chi P.

J Hematol Oncol. 2018 Jun 7;11(1):78. doi: 10.1186/s13045-018-0622-4.

15.

ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.

Marchiò C, Scaltriti M, Ladanyi M, Iafrate AJ, Bibeau F, Dietel M, Hechtman JF, Troiani T, López-Rios F, Douillard JY, Andrè F, Reis-Filho JS.

Ann Oncol. 2019 Jul 3. pii: mdz204. doi: 10.1093/annonc/mdz204. [Epub ahead of print]

PMID:
31268127
16.

Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro.

Tatematsu T, Sasaki H, Shimizu S, Okuda K, Shitara M, Hikosaka Y, Moriyama S, Yano M, Brown J, Fujii Y.

Mol Clin Oncol. 2014 Sep;2(5):725-730. Epub 2014 Jun 19.

17.

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.

Hong DS, Bauer TM, Lee JJ, Dowlati A, Brose MS, Farago AF, Taylor M, Shaw AT, Montez S, Meric-Bernstam F, Smith S, Tuch BB, Ebata K, Cruickshank S, Cox MC, Burris HA, Doebele RC.

Ann Oncol. 2019 Feb 1;30(2):325-331. doi: 10.1093/annonc/mdy539.

18.

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM.

N Engl J Med. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoa1714448.

19.

Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma.

Ziegler DS, Wong M, Mayoh C, Kumar A, Tsoli M, Mould E, Tyrrell V, Khuong-Quang DA, Pinese M, Gayevskiy V, Cohn RJ, Lau LMS, Reynolds M, Cox MC, Gifford A, Rodriguez M, Cowley MJ, Ekert PG, Marshall GM, Haber M.

Br J Cancer. 2018 Sep;119(6):693-696. doi: 10.1038/s41416-018-0251-2. Epub 2018 Sep 17.

PMID:
30220707
20.

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types.

Amatu A, Sartore-Bianchi A, Siena S.

ESMO Open. 2016 Mar 18;1(2):e000023. eCollection 2016. Review.

Supplemental Content

Support Center